Defy Medical places several hormone names beside several ways of delivering treatment. That makes the service relevant to an oral progesterone discussion, but it creates a possible reading error: matching every hormone to every route without a specific prescription record. A menu can describe the range of a practice without describing the medicine one person would receive.
This review, dated September 29, 2026, examines that distinction through Defy’s menopause, hormone-therapy and cost pages. It considers the purpose of a consultation, the missing capsule details and the difference between an illustrative care average and an actual charge. It does not verify an appointment, prescription or clinical result.
In this article
The verified offer is a clinical discussion about menopause
Defy’s menopause page describes telemedicine care for perimenopausal and menopausal patients, extended consultations and regular follow-up. Its treatment range includes hormone therapy alongside sexual-health services, supplements and skincare. These are different parts of the practice; a broad package of possible services is not evidence that each will belong in one plan.
The progesterone-purpose guide keeps the medication question more precise. A reader can ask what concern is being evaluated and what progesterone would contribute if proposed. The fact that a practice treats menopause does not establish that this hormone, an oral route or a particular additional service is appropriate.
The oral-capsule heading does not complete the formula
The hormone-therapy page explicitly lists oral BHRT capsules, as well as injections, topical preparations, pellets and suppositories. It discusses several hormones in the same broader service description. This supports the existence of oral hormone therapy as an option but does not identify the ingredients of a specific progesterone capsule.
There is no verified Prometrium product offer in these pages. Nor can a reader infer that a capsule combines hormones merely because a broader plan can include more than one. Thrivelab’s review reaches a similar identity question through a more detailed medication table. More entries can supply useful clues while still leaving the prescription itself unresolved.
A treatment’s purpose should be stated separately from its form
The FDA Prometrium label illustrates how specific a medicine’s stated role can be. It identifies prevention of endometrial hyperplasia in postmenopausal women with a uterus receiving conjugated estrogen tablets, and treatment of secondary amenorrhea. That exact record is not a label for every hormone capsule available through Defy.
If a clinician proposes an approved drug for a different use, FDA’s off-label explanation supports asking about the evidence and reasons. Off-label use of an approved medicine and use of a compounded preparation are different questions. Neither should disappear behind a general description of hormone balancing, and this review supplies no personal eligibility conclusion.
Ask for the ingredient list that belongs to the order
The capsule-excipients guide is relevant because Defy’s service menu does not publish a complete capsule shell and filler list for an individual prescription. A strength or hormone name would not answer that question on its own. The dispensing record needs to identify what is actually supplied.
For example, peanut oil appears in the Prometrium label, which carries a peanut-allergy contraindication. That fact must not be transferred to an unnamed Defy preparation, nor can the absence of a published ingredient list establish that another capsule is free of a particular allergen. The appropriate pharmacist can explain the precise product or compound.
The advertised monthly average is not a subscription price
Defy’s cost FAQ estimates that most female BHRT patients average under $200 a month during the first year, including consultations, laboratory work and medication, and often under $150 afterward. It expressly calls these illustrative averages, with individual costs affected by the treatment and other factors.
The same record says Defy does not charge a monthly fee or require a subscription: payment is due when a service is purchased. This is materially different from buying a fixed monthly supply of progesterone. Alpha Hormones’ review examines an actual recurring-membership model. A comparison should retain those different payment units rather than rank the two headline figures as if they purchased identical care.
A longer visit provides time for practical safety questions
Defy’s menopause description advertises hour-long consultations and ongoing monitoring. Those are opportunities to clarify the proposed medicine’s effects and follow-up, not proof that an adverse effect will never occur. The drowsiness guide identifies the kinds of practical concerns an oral-capsule discussion may need to cover.
The Prometrium label warns of dizziness and drowsiness and calls for caution around driving and machinery. It is a reason to obtain the correct counseling for the actual medicine, not an instruction to borrow another product’s timing. A sleep-related treatment goal and unwanted impairment deserve separate descriptions in the consultation.
Keep optional services and continuing responsibility visible
The menopause page describes pharmacy ordering through a patient portal and access to other services. An ordering function does not establish stock, a covered prescription, a shipment or the price of every item a clinician may discuss. Supplements and skincare should not be assumed necessary because they appear nearby on the website.
The follow-up questions guide helps establish who explains the plan, responds to a concern and coordinates a prescription question. Defy’s documentation supports a substantive clinical-service review. The exact capsule, any combination ingredients, financial responsibility and individual outcome remain to be established through the actual care and dispensing process, not through the breadth of the online menu.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Defy Medical: Menopause careProvider menopause consultation and follow-up offer; no confirmed individual medicine, outcome or availability · Checked 2026-09-29
- Defy Medical: Hormone therapyProvider treatment and route menu; oral hormone capsules do not establish a named progesterone formulation · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29
- FDA: Understanding Unapproved Use of Approved Drugs, Off LabelFederal explanation of off-label use of an approved drug; distinct from approval status of a compounded preparation · Checked 2026-09-29
- Defy Medical: How much does BHRT cost?Provider illustrative monthly cost averages, not fixed monthly billing or a capsule quote · Checked 2026-09-29